SUPPLEMENTAL MATERIAL

Complete Membership: Future Leaders In Growing Heart Failure Therapies (FLIGHT) investigators

Ochsner Medical Center
Northwestern
Penn Medicine
Minneapolis Heart Institute
MedStar
St. Vincent's
Duke Medical Center
University of Rochester Medical Center
Baylor
Baptist Health - Arkansas
St. Luke's Medical Center – Kansas City
Poriya Medical Center, Israel
Baptist Health – Arkansas
Rutgers
Mount Sinai
Montefiore
Medical University of South Carolina
Northwell
Penn Medicine
INTEGRIS
Barnes Jewish
Barnes Jewish
University of Maryland
St. Luke's Medical Center – Kansas City
University of Athens, Greece
Spectrum Health
Baptist Health, Memphis
Henry Ford Medical Center
St. Thomas West Hospital, Nashville

William Fischer III MD	St. Luke's Aurora Hospital, Milwaukee
Devin Mehta MD	Northwest Community Healthcare, Chicago
Tamas Alexy MD	University of Minnesota
Sophia Airhart MD	Providence Medical Center, Portland
Dominic Emerson MD	Cedars Sinai Medical Center
Antonio Christophy MD	Scripps – Mercy Memorial, California
Anthony Castleberry MD	University of Nebraska Medical Center
Andrew Shaffer MD	University of Minnesota
Jenna Kay MD	Providence Medical Center, Portland
Marshall Hyden MD	University of Nebraska Medical Center
Shashank Sinha MD	INOVA Fairfax
Jonathan Grinstein MD	University of Chicago
Sriram Rao MD	MedStar Washington
Nicole Cyrille Superville MD	Atrium Health, Charlotte
Eric Jeng MD	University of Florida
Priyesh Patel MD	Atrium Health, Charlotte
Jason Feliberti MD	Tampa General
David Snipelisky MD	Cleveland Clinic, Florida
Rohan Goswami MD	Mayo Clinic, Florida

Table S1. Data for Figure 1 on Trends in the Rate of 1-year Survival Across Clinical StudyGroups Over Time.

Clinical Trial or Study Name	Study Onset	Implant Strategy	Device(s)	1-Year Survival
REMATCH Trial ⁴	1998	DT	HeartMate XVE	52%
HeartMate II BTT Trial and continued- access protocol ^{92,93}	2005	BTT	HeartMate II	73%
HeartMate II DT Trial ⁹	2005	DT	HeartMate II vs XVE	HMII: 68% XVE: 55%
HeartMate II DT Trial continued- access protocol ⁷⁸	2007	DT	HeartMate II	HMII: 73%
INTERMACS study ⁹⁴	2008	BTT	HeartMate II	85%
ADVANCE Trial and continued-access protocol ^{79,95}	2008	BTT	HeartWare VAD	84%
ENDURANCE Trial ⁵⁵	2010	DT	HeartWare VAD HeartMate II	HVAD: 75% HMII: 78%
ENDURANCE Supplemental Trial ¹⁴	2013	DT	HeartWare VAD HeartMate II HVAD: 83% HMII: 82&	

MOMENTUM 3 ^{54,96,97,}	2014	BTT/BTC and DT	HMII HM 3	HMII BTT/BTC: 88% HM3 BTT/BTC: 92% HMII DT: 82% HM3 DT: 84%
------------------------------------	------	-------------------	--------------	--